98%
921
2 minutes
20
Background: Surveillance colonoscopy after polyp removal is recommended to prevent subsequent colorectal cancer (CRC). It is known that advanced adenomas have a substantially higher risk than non-advanced ones, but optimal intervals for surveillance remain unclear.
Design: We prospectively followed 156 699 participants who had undergone a colonoscopy from 2007 to 2017 in a large integrated healthcare system. Using multivariable Cox proportional hazards regression we estimated the subsequent risk of CRC and high-risk polyps, respectively, according to index colonoscopy polyps, colonoscopy quality measures, patient characteristics and the use of surveillance colonoscopy.
Results: After a median follow-up of 5.3 years, we documented 309 CRC and 3053 high-risk polyp cases. Compared with participants with no polyps at index colonoscopy, those with high-risk adenomas and high-risk serrated polyps had a consistently higher risk of CRC during follow-up, with the highest risk observed at 3 years after polypectomy (multivariable HR 5.44 (95% CI 3.56 to 8.29) and 8.35 (95% CI 4.20 to 16.59), respectively). Recurrence of high-risk polyps showed a similar risk distribution. The use of surveillance colonoscopy was associated with lower risk of CRC, with an HR of 0.61 (95% CI 0.39 to 0.98) among patients with high-risk polyps and 0.57 (95% CI 0.35 to 0.92) among low-risk polyps. Among 1548 patients who had high-risk polyps at both index and surveillance colonoscopies, 65% had their index polyps in the proximal colon and 30% had index and interval polyps in the same segments.
Conclusion: Patients with high-risk polyp findings were at higher risk of subsequent CRC and high-risk polyps and may benefit from early surveillance within 3 years. The subsite distribution of the index and recurrent high-risk polyps suggests the contribution of incomplete resection and missed lesions to the development of interval neoplasia.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1136/gutjnl-2023-331729 | DOI Listing |
Case Rep Genet
August 2025
Department of Clinical Genetics, Leiden University Medical Center, Leiden, the Netherlands.
is the primary high-risk predisposition gene for familial cutaneous melanoma. In the Netherlands, most carriers of pathogenic germline variants in harbor a unique, population-specific founder variant, c.225_243del, commonly referred to as p16-.
View Article and Find Full Text PDFIndian J Gastroenterol
September 2025
Department of Gastroenterology and Hepatology, Westmead Hospital, Sydney, NSW, 2145, Australia.
Endoscopic resection of pre-malignant polyps remains a cornerstone of colorectal cancer prevention. This review provides an evidence-based analysis of the current approaches to endoscopic colorectal polyp management. Cold snare resection is recommended for small and diminutive polyps.
View Article and Find Full Text PDFJ Can Assoc Gastroenterol
August 2025
Division of Gastroenterology, Montreal University Hospital Research Center (CRCHUM), Montreal, QC H2X 0C1, Canada.
Background And Study Aims: Recent research has identified an association between proximal sessile serrated lesions (SSLs) and an increased risk of advanced metachronous neoplasia (TMAN), with no significant impact from distal SSL. This study aimed to assess the risk of TMAN at follow-up colonoscopy after detecting proximal hyperplastic polyps (HP), adenomas, or their combination at the initial colonoscopy.
Methods: Medical records from patients who underwent colonoscopies in 2014 and 2015 were reviewed.
Int J Surg Case Rep
August 2025
Paediatrics Medicine, Services Hospital, Lahore, Pakistan.
Introduction: Adult intussusception is rare, and its occurrence following colonoscopy-especially after multiple polypectomies-is exceptionally uncommon. This case highlights a rare post-endoscopic complication with implications for early diagnosis and management.
Case Presentation: A 55-year-old man presented with abdominal pain, bloating, and nausea 24 h after colonoscopy with removal of nine polyps via cold snare technique.
Front Pharmacol
August 2025
Department of Physiology, College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
Type 2 (T2) inflammation underlies a substantial subset of moderate-to-severe asthma, contributing to persistent symptoms and frequent exacerbations. Dupilumab, a fully human immunoglobulin G subclass 4 (IgG4) monoclonal antibody, targets the interleukin-4 receptor alpha (IL-4Rα), thereby inhibiting both interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling-which are key cytokines driving T2 inflammation. This review examines the formulation, pharmacological profile, clinical efficacy, safety, and cost-effectiveness of dupilumab in the treatment of asthma, with an emphasis on its role across T2-high and selected T2-low phenotypes.
View Article and Find Full Text PDF